These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39207089)

  • 1. Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy.
    Sakunchotpanit G; Patil MK; Venkatesh K; Rohan TZ; Cheng D; Nambudiri VE
    Exp Dermatol; 2024 Sep; 33(9):e15169. PubMed ID: 39207089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
    Curti BD; Richards J; Hyngstrom JR; Daniels GA; Faries M; Feun L; Margolin KA; Hallmeyer S; Grose M; Zhang Y; Li A; Andtbacka RHI
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
    Rudin CM; Pandha HS; Zibelman M; Akerley WL; Harrington KJ; Day D; Hill AG; O'Day SJ; Clay TD; Wright GM; Jennens RR; Gerber DE; Rosenberg JE; Ralph C; Campbell DC; Curti BD; Merchan JR; Ren Y; Schmidt EV; Guttman L; Gupta S
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36669791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.
    Lutzky J; Sullivan RJ; Cohen JV; Ren Y; Li A; Haq R
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6059-6066. PubMed ID: 36651961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    Andtbacka RHI; Curti B; Daniels GA; Hallmeyer S; Whitman ED; Lutzky J; Spitler LE; Zhou K; Bommareddy PK; Grose M; Wang M; Wu C; Kaufman HL
    J Clin Oncol; 2021 Dec; 39(34):3829-3838. PubMed ID: 34464163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
    Silk AW; O'Day SJ; Kaufman HL; Bryan J; Norrell JT; Imbergamo C; Portal D; Zambrano-Acosta E; Palmeri M; Fein S; Wu C; Guerreiro L; Medina D; Bommareddy PK; Zloza A; Fox BA; Ballesteros-Merino C; Ren Y; Shafren D; Grose M; Vieth JA; Mehnert JM
    Cancer Immunol Immunother; 2023 Jun; 72(6):1405-1415. PubMed ID: 36445410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P; Tang R; Luo M
    Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.
    Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR
    Virol J; 2011 Jan; 8():22. PubMed ID: 21241513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
    Tran TQ; Grein J; Selman M; Annamalai L; Yearley JH; Blumenschein WM; Sadekova S; Chackerian AA; Phan U; Wong JC
    Mol Ther Oncol; 2024 Jun; 32(2):200807. PubMed ID: 38745749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
    Smithy JW; Pianko MJ; Maher C; Postow MA; Shoushtari AN; Momtaz P; Chapman PB; Wolchok JD; Park JH; Callahan MK
    J Immunother; 2021 Jan; 44(1):9-15. PubMed ID: 33290361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab.
    Sancho-Araiz A; Parra-Guillen ZP; Troconiz IF; Freshwater T
    Clin Pharmacol Ther; 2024 Nov; 116(5):1304-1313. PubMed ID: 39037559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis.
    Wang C; Lu N; Yan L; Li Y
    Virol J; 2023 Nov; 20(1):252. PubMed ID: 37919738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.
    Beasley GM; Nair SK; Farrow NE; Landa K; Selim MA; Wiggs CA; Jung SH; Bigner DD; True Kelly A; Gromeier M; Salama AK
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33875611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
    Chiu M; Armstrong EJL; Jennings V; Foo S; Crespo-Rodriguez E; Bozhanova G; Patin EC; McLaughlin M; Mansfield D; Baker G; Grove L; Pedersen M; Kyula J; Roulstone V; Wilkins A; McDonald F; Harrington K; Melcher A
    Expert Opin Biol Ther; 2020 Jun; 20(6):635-652. PubMed ID: 32067509
    [No Abstract]   [Full Text] [Related]  

  • 18. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
    Puzanov I; Milhem MM; Minor D; Hamid O; Li A; Chen L; Chastain M; Gorski KS; Anderson A; Chou J; Kaufman HL; Andtbacka RH
    J Clin Oncol; 2016 Aug; 34(22):2619-26. PubMed ID: 27298410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.